CY1107388T1 - Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων - Google Patents

Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων

Info

Publication number
CY1107388T1
CY1107388T1 CY20081100391T CY081100391T CY1107388T1 CY 1107388 T1 CY1107388 T1 CY 1107388T1 CY 20081100391 T CY20081100391 T CY 20081100391T CY 081100391 T CY081100391 T CY 081100391T CY 1107388 T1 CY1107388 T1 CY 1107388T1
Authority
CY
Cyprus
Prior art keywords
alkyl
substituted
unsubstituted
cycloalkyl
group selected
Prior art date
Application number
CY20081100391T
Other languages
English (en)
Inventor
Nathan Bryan Mantlo
Cano Ivan Collado
Samuel James Dominianni
Garret Jay Junior Etgen
Cristina Garcia-Paredes
Richard Duane Johnston
Michael Edward Letourneau
Michael John Martinelli
Daniel Ray Mayhugh
Ashraf Saeed
Richard Craig Thompson
Xiadong Wang
David Scott Coffey
Christopher Randall Schmid
Jeffrey Thomas Vicenzi
Yanping Xu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1107388T1 publication Critical patent/CY1107388T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cultivation Of Plants (AREA)

Abstract

Η παρούσα εφεύρεση εστιάζεται σε ενώσεις οι οποίες αντιπροσωπεύονται από τον ακόλουθο δομικό τύπο (Ι'), και φαρμακευτικώς αποδεκτά άλατα, επιδιαλυτωμένα άλατα και ένυδρα άλατα αυτών, το R1 είναι μια υποκατεστημένη ή μη-υποκατεστημένη ομάδα επιλεγμένη από C1-C8 αλκύλιο, αρυλο-C0-2-αλκύλιο, ετεροαρυλο-C0-2-αλκύλιο, C3-C6 κυκλοαλκυλαρυλο-C0-2-αλκύλιο ή φαινύλιο. To W είναι Ο ή S. To R2 είναι Η ή μια υποκατεστημένη ή μη-υποκατεστημένη ομάδα επιλεγμένη από C1-C6 αλκύλιο, C3-C6 κυκλοαλκύλιο και ετεροαρύλιο. To Χ είναι ένας C2-C5 αλκυλενο συνδέτης όπου ένα άτομο άνθρακα του συνδέτη μπορεί να αντικατασταθεί με Ο, ΝΗ, ή S. Το Υ είναι C, Ο, S, ΝΗ ή ένας απλός δεσμός. Περαιτέρω, το Ε είναι (CH2)nCOOH, όπου το n είναι 0, 1, 2 ή 3, ή C(R3)(R4)A, όπου το Α είναι μια όξινη δραστική ομάδα όπως καρβοξύλιο, καρβοξαμίδιο υποκατεστημένο ή μη-υποκατεστημένο σουλφοναμίδιο, ή υποκατεστημένο ή μη-υποκατεστημένο τετραζόλιο. To R3 είναι Η, κορεσμένο ή ακόρεστο C1-C5 αλκύλιο, C1-C5 αλκοξυ. Επιπροσθέτως, το R4 είναι Η, αλογόνο, μια υποκατεστημένη ή μη-υποκατεστημένη ομάδα επιλεγμένη από C1-C5 αλκύλιο, C1-C5 αλκοξυ, C3-C6 κυκλοαλκύλιο, αρυλοC0-C4αλκύλιο και φαινύλιο, ή τα R3 και R4 συνδυάζονται για να σχηματίσουν ένα C3-C4 κυκλοαλκύλιο.
CY20081100391T 2000-11-10 2008-04-10 Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων CY1107388T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24731700P 2000-11-10 2000-11-10
EP01989704A EP1335908B1 (en) 2000-11-10 2001-11-09 Peroxisome proliferator activated receptor alpha agonists

Publications (1)

Publication Number Publication Date
CY1107388T1 true CY1107388T1 (el) 2012-12-19

Family

ID=22934453

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100391T CY1107388T1 (el) 2000-11-10 2008-04-10 Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων

Country Status (35)

Country Link
US (3) US7304062B2 (el)
EP (1) EP1335908B1 (el)
JP (1) JP4243101B2 (el)
KR (1) KR100839705B1 (el)
CN (1) CN1479728A (el)
AR (1) AR031305A1 (el)
AT (1) ATE386026T1 (el)
AU (3) AU2859202A (el)
BR (1) BR0114986A (el)
CA (1) CA2421154A1 (el)
CY (1) CY1107388T1 (el)
CZ (1) CZ20031283A3 (el)
DE (1) DE60132799T2 (el)
DK (1) DK1335908T3 (el)
EA (1) EA006920B1 (el)
EC (1) ECSP034595A (el)
ES (1) ES2300378T3 (el)
HK (1) HK1058790A1 (el)
HR (1) HRP20030365A2 (el)
HU (1) HUP0301655A2 (el)
IL (2) IL154840A0 (el)
MX (1) MXPA03004141A (el)
MY (1) MY157884A (el)
NO (1) NO20032059L (el)
NZ (1) NZ524569A (el)
PE (1) PE20020693A1 (el)
PL (1) PL362692A1 (el)
PT (1) PT1335908E (el)
SI (1) SI1335908T1 (el)
SK (1) SK5412003A3 (el)
SV (1) SV2003000727A (el)
TW (1) TW200716572A (el)
UA (1) UA82048C2 (el)
WO (1) WO2002038553A2 (el)
ZA (1) ZA200302517B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043997A1 (en) * 2001-11-15 2003-05-30 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1517882A1 (en) 2002-06-19 2005-03-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
CA2574308C (en) * 2004-07-27 2014-03-25 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
KR100803481B1 (ko) * 2004-07-27 2008-02-14 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
WO2006068199A1 (ja) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
AR052888A1 (es) * 2005-01-28 2007-04-11 Lilly Co Eli Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
CA2600074A1 (en) * 2005-03-23 2006-09-28 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminophenylalkanoic acid derivative
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
CN101616900A (zh) * 2007-02-23 2009-12-30 伊莱利利公司 过氧化物增殖物激活受体调节剂
CN101657433A (zh) 2007-03-29 2010-02-24 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
WO2010002712A2 (en) * 2008-06-30 2010-01-07 3M Innovative Properties Company Method of crystallization
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
EP2380884B1 (en) 2008-12-01 2014-02-12 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
US20110167512A1 (en) * 2009-03-02 2011-07-07 Nunhems B.V. Hybrid artichoke variety nun 4006 ar
US8575430B2 (en) * 2010-03-02 2013-11-05 Nunhems, B.V. Hybrid artichoke variety NUN 4006 AR
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US20100245582A1 (en) * 2009-03-25 2010-09-30 Syclipse Technologies, Inc. System and method of remote surveillance and applications therefor
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8648233B2 (en) * 2010-09-20 2014-02-11 Nunhems B.V. Hybrid artichoke variety NUN 4021 AR
US8669420B2 (en) 2012-02-29 2014-03-11 Nunhems B.V. Hybrid artichoke variety NUN 4060 AR
EP2822931B1 (en) * 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
MX2015007433A (es) * 2012-12-20 2015-12-07 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
EA201690230A1 (ru) * 2013-09-06 2016-07-29 Инсепшн 2, Инк. Соединения триазолона и их применения
RU177130U1 (ru) * 2017-11-29 2018-02-09 Владимир Алексеевич Коннов Плита изоляционная облицовочная
EP4135057A4 (en) 2020-04-10 2023-09-20 Panasonic Intellectual Property Management Co., Ltd. THERMOELECTRIC TRANSDUCER, THERMOELECTRIC MODULE, BINDER AND METHOD FOR MANUFACTURING THERMOELECTRIC TRANSDUCER
CN112774869B (zh) * 2020-12-25 2022-09-16 厦门紫金矿冶技术有限公司 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
DE19517505A1 (de) * 1995-05-12 1996-11-14 Bayer Ag Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
JP3193706B2 (ja) 1997-10-17 2001-07-30 山之内製薬株式会社 アミド誘導体又はその塩
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
USPP14578P2 (en) * 2002-09-23 2004-03-09 Plant Sciences, Inc. Artichoke plant named ‘PS-MSC0003’

Also Published As

Publication number Publication date
US20040102500A1 (en) 2004-05-27
NO20032059L (no) 2003-06-24
US20090062358A1 (en) 2009-03-05
EA200300558A1 (ru) 2004-02-26
KR100839705B1 (ko) 2008-06-19
IL154840A0 (en) 2003-10-31
AU2002228592B8 (en) 2006-08-24
CA2421154A1 (en) 2002-05-16
WO2002038553A2 (en) 2002-05-16
CZ20031283A3 (cs) 2003-09-17
TW200716572A (en) 2007-05-01
EP1335908B1 (en) 2008-02-13
NO20032059D0 (no) 2003-05-08
JP4243101B2 (ja) 2009-03-25
ZA200302517B (en) 2004-06-30
US7304062B2 (en) 2007-12-04
DK1335908T3 (da) 2008-06-02
SK5412003A3 (en) 2004-01-08
HUP0301655A2 (hu) 2003-12-29
AR031305A1 (es) 2003-09-17
AU2006202811A1 (en) 2006-07-20
PT1335908E (pt) 2008-05-08
UA82048C2 (uk) 2008-03-11
ES2300378T3 (es) 2008-06-16
DE60132799D1 (de) 2008-03-27
EP1335908A2 (en) 2003-08-20
JP2004513166A (ja) 2004-04-30
BR0114986A (pt) 2003-09-23
DE60132799T2 (de) 2009-03-19
SV2003000727A (es) 2003-01-13
ATE386026T1 (de) 2008-03-15
PL362692A1 (en) 2004-11-02
EA006920B1 (ru) 2006-04-28
HRP20030365A2 (en) 2003-08-31
US7868225B2 (en) 2011-01-11
AU2859202A (en) 2002-05-21
MY157884A (en) 2016-08-01
SI1335908T1 (sl) 2008-08-31
PE20020693A1 (es) 2002-08-05
MXPA03004141A (es) 2003-08-19
US20090044299A1 (en) 2009-02-12
IL154840A (en) 2009-09-22
NZ524569A (en) 2006-05-26
HK1058790A1 (en) 2004-06-04
AU2002228592B2 (en) 2006-04-27
KR20030048133A (ko) 2003-06-18
CN1479728A (zh) 2004-03-03
WO2002038553A3 (en) 2003-05-01
ECSP034595A (es) 2003-06-25

Similar Documents

Publication Publication Date Title
CY1107388T1 (el) Αγωνιστες αλφα υποδοχεα ενεργοποιουμενου απο πολλαπλασιαστες υπεροξυσωματων
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
CY1107886T1 (el) Αναστολεις κινασης ως θεραπευτικοι παραγοντες
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
ATE415160T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
CY1108352T1 (el) Υποκατασταθεισες 1,4-βενζοδιαζεπινες και χρησεις τους για την αγωγη του καρκινου
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
CY1106947T1 (el) Ανταγωνιστες υποδοχεα θρομβινης
CO5150173A1 (es) Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
CO5611126A2 (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
ES2192520T3 (es) Composicion farmaceutica.
DK0502169T3 (da) Piperazinderivater
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
EA200400748A1 (ru) Агонисты рецепторов, активируемых пероксисомным пролифератором
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
DE60327922D1 (de) Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DK0677042T3 (da) Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler
EA200200729A1 (ru) Производные 4-фенил-1-пиперазинила, -пиперидинила и -тетрагидропиридила
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3